RespireRx Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on RespireRx Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date RespireRx Pharmaceuticals Inc Strategy Report
- Understand RespireRx Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
RespireRx Pharmaceuticals Inc (RespireRx), formerly Cortex Pharmaceuticals, Inc. involved in the discovery, development, and commercialization of innovative products for the treatment of various respiratory disorders (RD) and CNS problems. RespireRx focuses on attention deficit hyperactivity disorder, obstructive sleep apnea (OSA), spinal cord injury and other neurological disorders. The company's lead product is Dronabinol, an oral capsule drug product which is being evaluated for the treatment of OSA. The company's other pipeline products include CX1739, CX717, CX1942 and others. RespireRx is headquartered in Glen Rock, New Jersey, the US.
Headquarters
United States of America
Address
126 Valley Rd Ste C, Glen Rock, New Jersey, 07452-1796
Website
www.respirerx.com
Telephone
1 201 4444947
No of Employees
2
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RSPI (OTC)
EPS
XYZ
Market Cap*
$330,000
Net Profit Margin (0 vs)
XYZ
0.0%
* As of and is in US$
RespireRx Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Dronabinol: |
| Obstructive Sleep Apnea |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, RespireRx Pharmaceuticals entered into an agreement Cantheon Capital for the financing of anticipated research and development costs. |
| 2023 | Contracts/Agreements | In April, the company and University College London partnered to study the use of AMPAkines for the treatment of GRIA disorders. |
| 2023 | Contracts/Agreements | In March, the company through its subsidiary and ResolutionRx Ltd entered into a services agreement for clinical research and other related services with iNGENu CRO Pty Ltd. |
Competitor Comparison
| Key Parameters | RespireRx Pharmaceuticals Inc | Athersys Inc | MediciNova Inc | Celgene Corp | Mylan Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Glen Rock | Cleveland | La Jolla | Summit | Morgantown |
| State/Province | New Jersey | Ohio | California | New Jersey | West Virginia |
| No. of Employees | 2 | 24 | 13 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Arnold S. Lippa, Ph.D. | Chairman; Chief Executive Officer; President | Executive Board | 2015 | 76 |
| Jeff Margolis | Chief Financial Officer; Director; Senior Vice President; Secretary; Treasurer | Executive Board | 2018 | 67 |
| Richard Purcell | Senior Vice President - Research & Development | Senior Management | 2014 | - |
| David Dickason | Senior Vice President - Pre-clinical Product Development | Senior Management | 2020 | - |
| Joseph Siegelbaum | Director | Non Executive Board | 2023 | 75 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward